AI-Assisted Drug Discovery Software Market Forecast 2026-2032 | 8.39% CAGR Drives Market Towards $921.74 Million amid Generative AI and Cloud Adoption
Dublin, Nov. 19, 2026 (GLOBE NEWSWIRE) -- "AI-Assisted Drug Discovery Software Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.
The AI-Assisted Drug Discovery Software Market research report provides an in-depth assessment of technologies, scientific workflows, adoption conditions, governance priorities, and regional developments shaping the industry. The market is projected to reach USD 569.69 million in 2026 and expand at a compound annual growth rate (CAGR) of 8.39% to USD 921.74 million by 2032.
Market Overview
AI-assisted drug discovery software applies machine learning, generative models, knowledge graphs, molecular simulation, and data analytics across:
Adoption is increasing as pharmaceutical, biotechnology, academic, and research organizations seek to integrate diverse biological and chemical datasets while improving the speed, reproducibility, and prioritization of laboratory work. Market intelligence covering these developments supports strategic planning and the identification of high-value applications and partnership opportunities.
Workflow and Technology Developments
Drug discovery is moving from isolated computational experiments toward connected workflows encompassing literature mining, omics interpretation, structure-based design, molecular generation, property prediction, experiment planning, and laboratory automation.
Artificial intelligence can rank targets, identify molecular patterns, propose compounds, and reduce repetitive analysis. Generative and multimodal systems can also connect chemical, genomic, structural, phenotypic, and clinical information. However, successful deployment continues to require:
Regional Market Landscape
Country-level coverage includes Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, the United Kingdom, and the United States. These insights enable organizations to compare market-entry conditions, anticipate local barriers, and prioritize regions aligned with their research and commercialization capabilities.
Collaboration and Policy Environment
ASEAN, BRICS, the European Union, G7, GCC, and NATO-linked ecosystems influence research collaboration, infrastructure development, data practices, cybersecurity, and responsible AI standards. Their differing governance models and investment priorities affect cross-border data exchange, talent development, and access to scientific resources.
Strategic Priorities for Industry Leaders
These priorities provide a practical basis for mitigating technical and operational risks while strengthening competitive positioning through disciplined AI adoption.
Key Takeaways from This Report
Key Topics Covered
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. AI-Assisted Drug Discovery Software Market, by Technique
7.1. Introduction
7.2. Deep Learning
7.2.1. Autoencoders
7.2.2. Convolutional Neural Networks
7.2.3. Recurrent Neural Networks
7.3. Ligand Based
7.4. Machine Learning
7.4.1. Reinforcement Learning
7.4.2. Supervised Learning
7.4.3. Unsupervised Learning
7.5. Structure Based
8. AI-Assisted Drug Discovery Software Market, by Deployment Model
8.1. Introduction
8.2. Cloud
8.3. Hybrid
8.4. On Premises
9. AI-Assisted Drug Discovery Software Market, by Therapeutic Area
9.1. Introduction
9.2. Cardiovascular
9.3. Central Nervous System
9.4. Infectious Diseases
9.5. Oncology
10. AI-Assisted Drug Discovery Software Market, by Application
10.1. Introduction
10.2. Clinical Trial Design
10.3. Lead Optimization
10.4. Pharmacovigilance
10.5. Target Identification
11. AI-Assisted Drug Discovery Software Market, by End User
11.1. Introduction
11.2. Biotechnology Companies
11.3. Contract Research Organizations
11.4. Pharmaceutical Companies
12. AI-Assisted Drug Discovery Software Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. AI-Assisted Drug Discovery Software Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. AI-Assisted Drug Discovery Software Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Aitia Inc.
16.2. Ardigen Sp. z o.o.
16.3. Atomwise Inc.
16.4. BenevolentAI Limited
16.5. Berg LLC
16.6. BioSymetrics, Inc.
16.7. BioXcel Therapeutics, Inc.
16.8. Cloud Pharmaceuticals, Inc.
16.9. Cresset Group Ltd.
16.10. Cyclica Inc.
16.11. Deep Genomics Inc.
16.12. Eagle Genomics Ltd.
16.13. Exscientia PLC
16.14. GNS Healthcare Inc.
16.15. Iktos SAS
16.16. Insilico Medicine, Inc.
16.17. Isomorphic Labs Ltd.
16.18. NVIDIA Corporation
16.19. Owkin SAS
16.20. Peptilogics, Inc.
16.21. Recursion Pharmaceuticals, Inc.
16.22. Schrodinger, Inc.
16.23. Valo Health, Inc.
16.24. Verge Genomics, Inc.
16.25. XtalPi Holdings Limited
17. Key Experts
LIST OF FIGURES [21]
LIST OF TABLES [300]
For more information about this report visit https://www.researchandmarkets.com/r/vamk88
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.